Structure Therapeutics (GPCR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- GPCR Therapeuticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 27/100 (MEDIUM), 176.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
- Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus
- Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?
- Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
- Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
- Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
- VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’
- NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Target-Engagement Prediction From Molecular Structure, In Vitro and Animal Data: A Tutorial for Early Assessment of Clinical Drug Exposure and Therapeutic/Adverse Potential Using the ANDROMEDA and PLATO Software on the InSilicoTrials Platform. — CPT Pharmacometrics Syst Pharmacol 2026 Nov PMID 42886006
- Longitudinal Changes in Left Ventricular Structure and Function During a Dietary Weight-Management Trial in Adults with Heart Failure, Type 2 Diabetes, and Obesity: A Secondary Analysis of Pro-HEART. — Nutrients 2026 Oct 1 PMID 42884690
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Structure Therapeutics.
Full GPCR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.